HONG KONG — The dozen countries on both sides of the ocean that have signed up for the Trans Pacific Partnership (TPP) have grand plans to boost access and mobility for medical products among themselves, but how individual markets will be affected will ultimately depend on supporting policies at the national level.
HONG KONG – Yet another prominent Chinese biopharma company may be going private, saying goodbye to a U.S. stock market that is much less welcoming that it once was.
HONG KONG – A promising cancer orphan drug could soon be available in a string of major and emerging Asian markets, marking the next step in a multinational partnership for global commercialization and research.
HONG KONG – A promising cancer orphan drug could soon be available in a string of major and emerging Asian markets, marking the next step in a multinational partnership for global commercialization and research.
HONG KONG – The Chinese stock market has spent the first three weeks of the year in a virtual free fall, hitting a year-long bottom last Friday. Two weeks of constant drops have spooked overseas investors who have pulled their money out of the market. The good news for biopharma investors, however, is that the space has held up relatively well, and the overall pharma market in China is still expected to experience double-digit growth.
HONG KONG – The Chinese stock market has spent the first three weeks of the year in a virtual free fall, hitting a year-long bottom last Friday. Two weeks of constant drops have spooked overseas investors who have pulled their money out of the market.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept, a win that opens up the European market for a company that is working to become a global top-tier biosimilar maker.
